Dr. Mary Lynne Hedley is a senior fellow and strategic advisor at The Broad Institute of MIT and Harvard and co-founder, former president, director, and chief operating officer at TESARO, Inc.
Mary Lynne has extensive experience in the discovery and development of new medicines, formerly serving as Executive Vice President and Chief Scientific Officer at MGI Pharma, Executive Vice President of Eisai Corporation of North America, and Executive Vice President of Operations and Chief Scientific Officer of Abraxis Bio Science.
Mary Lynne also sits on the Veeva Systems (NASDAQ: VEEV) board of directors, is a member of the Helsinn Holding pharmaceutical company’s board of directors, and is on the board of directors of Eli Lilly and Company.
Mary Lynne holds a PhD in immunology from the University of Texas Southwestern Medical Center and a BS in microbiology from Purdue University. In addition, she completed 2 consecutive postdoctoral fellowships at Harvard University.
